Diagnolita is the prostate cancer diagnostic test which allows to estimate the likelihood of the positive biopsy and to aid in the decision for biopsy. In this test two scores are determined, one of which evaluates the possibility of the positive biopsy, while the other estimates the risk of clinically significant cancer. Cancer is considered clinically significant if the Gleason score is equal to or higher than 7. The test can be performed using urine samples collected with or without DRE (prostate massage). A biopsy is required to confirm the diagnosis of prostate cancer.

Implementing the prostate cancer diagnostic test the quantities of prostate cancer-specific biomarkers are determined in the first catch urine specimens. Urine specimens are collected using special tubes with a funnel that ensures that the first 10 ml of the urine are collected. Once in the tube, the urine is immediately mixed with the stabilizing medium that protects the nucleic acids from degradation. The stabilized urine specimens are shipped to Diagnolita’s laboratory for analysis.

FEATURES OF DIAGNOLITA’S PROSTATE CANCER TEST:

• Non-invasive – patient‘s urine specimen is used for analysis
• Versatile– can be performed with or without DRE
• Cost efficient – one test estimates both the likelihood of cancer and the risk of high-grade cancer
• Sensitive and specific – based on detection of well-defined molecular biomarkers